Clinical Trials for Malaria (Plasmodium Falciparum): 2 Recruiting

Every trial in this listing is drawn from ClinicalTrials.gov, the federal registry of clinical research operated by the U.S. National Library of Medicine. Each entry on ClinicalTrials.gov is filed by the study sponsor and includes a unique NCT identifier, study design, eligibility criteria, intervention details, sponsor information, sites, and status. TrialFinder reorganizes that public registry data so it is browsable by condition, sponsor, phase, and geography.

Malaria (Plasmodium Falciparum) is a relatively narrow research area in this dataset, with 2 trials out of the 7,755 indexed (about 0.03%). Smaller research footprints are common for rare conditions and for areas where standard-of-care therapy is already well established. Eligible patients may need to travel to participating sites. The most common intervention being tested in Malaria (Plasmodium Falciparum) trials is 5µg R21/50µg Matrix-M (biological-class), followed by 10µg R21/50µg Matrix-M, Artemether/lumefantrine tablets. Intervention type matters because it shapes what participation looks like — drug studies typically involve scheduled dosing and bloodwork, device trials involve a procedure or implant, and behavioral studies may only require visits and surveys.

Clinical trials are how new therapies, devices, and procedures get tested before the U.S. Food and Drug Administration decides whether to approve them for general use. Federal law requires most U.S.-based interventional trials to be registered on ClinicalTrials.gov, and many international trials are listed voluntarily. That makes the registry the most comprehensive single window into active medical research for Malaria (Plasmodium Falciparum) and other conditions.

Government science agencies play an unusually large role in Malaria (Plasmodium Falciparum) research, funding roughly 50% of the listed trials. Industry contributes about 0% and academic centers about 50%. A heavy public-funding share is common for conditions of major public-health concern or for research areas where the commercial market alone would not support late-stage development.

The sponsor matters because it shapes how a trial is designed and run. Industry-sponsored studies are usually tightly protocoled and tied to a regulatory submission. Academic studies often investigate questions a commercial sponsor would not, including comparisons between existing therapies, mechanism-of-disease research, and approaches for patient subgroups too small to be commercially attractive. Government-funded research, including programs run by the National Institutes of Health, frequently focuses on public-health priorities, prevention, and long-term outcomes.

Phase 2 trials test whether the therapy actually works in the target patient population, usually with 100 to 300 participants. The FDA looks at Phase 2 evidence to decide whether the larger, more expensive Phase 3 program is worth running.

Almost every listed Malaria (Plasmodium Falciparum) trial in this dataset is currently recruiting — 2 of 2 studies are actively seeking participants. That high active rate reflects the dataset's focus on enrollment-open studies and means there are real, near-term opportunities for eligible patients to take part.

The development phase tells you what question a trial is asking. Early-phase studies (Phase 1 and Early Phase 1) are about safety and dosing. Phase 2 studies look for an efficacy signal. Phase 3 studies generate the evidence regulators use to decide whether a therapy is approved for general clinical use. Phase 4 studies happen after approval and look at long-term outcomes in real-world settings. Trials labeled "Not Applicable" are typically observational or device studies that do not fit the drug-trial framework.

Malaria (Plasmodium Falciparum) is a relatively narrow research area in this dataset, with 2 trials out of the 7,755 indexed (about 0.03%). Smaller research footprints are common for rare conditions and for areas where standard-of-care therapy is already well established. Eligible patients may need to travel to participating sites.

Across the full TrialFinder dataset of 7,755 indexed studies and 2,541 distinct conditions, the most heavily researched areas tend to cluster around oncology, metabolic disease, and neurology — areas with both large patient populations and active commercial investment. Rare diseases and pediatric conditions usually have smaller absolute trial counts but a higher share of academically and federally funded studies. The Malaria (Plasmodium Falciparum) mix above reflects where this condition currently sits on that spectrum.

Malaria (Plasmodium Falciparum) trial eligibility varies by study, but Phase 2 work — which is heavily represented in this dataset — usually requires confirmed diagnosis, defined disease activity, and limits on prior therapies. Read each trial's inclusion and exclusion list carefully and bring it to your physician before contacting the study team.

Practical participation considerations include travel to a study site (most trials require in-person visits at a hospital or research center), time commitment (visits often run hours each, with some trials lasting years), and out-of-pocket costs. Trial sponsors typically cover the investigational therapy and study-required tests, but standard-of-care costs may still be billed to the participant or their insurer. A study coordinator can clarify which costs are covered before consent.

Patients and caregivers researching Malaria (Plasmodium Falciparum) trials should treat any listing as a starting point for a conversation with their physician. The treating clinician knows the patient's full medical history, current medications, and overall treatment plan, and is best positioned to flag interactions and risks that a registry summary cannot capture. A second medical opinion from a specialist treating Malaria (Plasmodium Falciparum) is often valuable before consenting to participate.